Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enterovirus A vaccine - Takeda

Drug Profile

Enterovirus A vaccine - Takeda

Alternative Names: Coxsackie virus vaccine - Takeda; EV71 vaccine; Hand, foot and mouth disease (HFMD) vaccine - Takeda; HFMDVax; INV 21; TAK-021

Latest Information Update: 28 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SingVax
  • Developer Takeda Pharmaceuticals USA
  • Class Enterovirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Enterovirus A infections

Most Recent Events

  • 28 Nov 2017 Enterovirus A vaccine is still in phase I trials for Enterovirus A infections in Singapore
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Enterovirus A infections(Prevention, In volunteers) in Singapore (Injection)
  • 31 May 2013 Inviragen has been acquired by Takeda Pharmaceuticals USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top